Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
April 28, 2022 at 02:37 pm
Share
Hunan Fangsheng Pharmaceutical Co., Ltd. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was CNY 1,534.86 million compared to CNY 1,251.61 million a year ago. Revenue was CNY 1,566.97 million compared to CNY 1,278.77 million a year ago. Net income was CNY 70.04 million compared to CNY 63.79 million a year ago. Basic earnings per share from continuing operations was CNY 0.16 compared to CNY 0.15 a year ago. Diluted earnings per share from continuing operations was CNY 0.16 compared to CNY 0.15 a year ago.
Hunan Fangsheng Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company primarily operates its businesses through two segments. The Pharmaceutical Manufacturing Business segment mainly provides cardiovascular and cerebrovascular drugs, orthopedic drugs, respiratory drugs, pediatric drugs, gynecological drugs and anti-infective drugs. The Company's main products include Xuesetong dispersible tablets, Xuesetong tablets, Garcinia bone-strengthening tablets, Dieda Huoxue capsules, Lysine Vitamin B12 granules, Cefuroxime tablets, Jinying capsules, Pudilan anti-inflammatory tablets, Xiaoer Jingxing cough granules, Ezetimibe tablets, Xuanqi bone-strengthening tablets, Qiangli Loquat Paste (honey-refined), Qiangli Loquat Dew and others. The Others segment is mainly engaged in other businesses such as medical services, pharmaceutical commerce and drug sales.